Prevention of dementia: lessons from SYST-EUR and PROGRESS
- PMID: 15537524
- DOI: 10.1016/j.jns.2004.09.015
Prevention of dementia: lessons from SYST-EUR and PROGRESS
Abstract
Hypertension is one of the principal risk factors for cerebrovascular diseases, closely correlated also with cognitive decline and dementia. Data from recent therapeutic trials (SYST-EUR, PROGRESS) open the way toward the prevention of dementia (vascular or Alzheimer's type) by antihypertensive treatments. The results of these two studies suggest different mechanisms of action of antihypertensive drugs in the prevention of cognitive decline. The use of angiotensin converting enzyme (ACE) inhibitors, with or without diuretics, resulted in decrease incidence of stroke-related dementia, but dementia without stroke was not reduced. With the dihydropyridine calcium antagonists, a reduction in both Alzheimer's type and vascular dementia was demonstrated.
Similar articles
-
[Cognitive functions and hypertension].Arch Mal Coeur Vaiss. 2005 Feb;98(2):133-9. Arch Mal Coeur Vaiss. 2005. PMID: 15787305 Review. French.
-
Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.Expert Rev Neurother. 2009 Sep;9(9):1413-31. doi: 10.1586/ern.09.89. Expert Rev Neurother. 2009. PMID: 19769454 Review.
-
Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment.Pharmacotherapy. 2008 Mar;28(3):366-75. doi: 10.1592/phco.28.3.366. Pharmacotherapy. 2008. PMID: 18294116 Review.
-
[Cognitive decline and hypertension].Arch Mal Coeur Vaiss. 2003 Jan;96(1):47-51. Arch Mal Coeur Vaiss. 2003. PMID: 12613149 Review. French.
-
Antihypertensive treatments, cognitive decline, and dementia.J Alzheimers Dis. 2010;20(3):903-14. doi: 10.3233/JAD-2010-091552. J Alzheimers Dis. 2010. PMID: 20182022 Review.
Cited by
-
Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.Mol Med. 2011 Mar-Apr;17(3-4):149-62. doi: 10.2119/molmed.2010.00180. Epub 2010 Dec 17. Mol Med. 2011. PMID: 21170472 Free PMC article.
-
Post-Translational Modification of Cav1.2 and its Role in Neurodegenerative Diseases.Front Pharmacol. 2022 Jan 17;12:775087. doi: 10.3389/fphar.2021.775087. eCollection 2021. Front Pharmacol. 2022. PMID: 35111050 Free PMC article. Review.
-
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.Br J Clin Pharmacol. 2012 Apr;73(4):504-17. doi: 10.1111/j.1365-2125.2011.04134.x. Br J Clin Pharmacol. 2012. PMID: 22035455 Free PMC article. Review.
-
An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3.Am J Med Genet B Neuropsychiatr Genet. 2009 Jul 5;150B(5):721-35. doi: 10.1002/ajmg.b.30899. Am J Med Genet B Neuropsychiatr Genet. 2009. PMID: 19105203 Free PMC article.
-
Potential surrogate markers of cerebral microvascular angiopathy in asymptomatic subjects at risk of stroke.Eur Radiol. 2009 Apr;19(4):1011-8. doi: 10.1007/s00330-008-1202-8. Epub 2008 Nov 6. Eur Radiol. 2009. PMID: 18987865
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous